Novel pharmacotherapy for burn wounds: what are the advancements

References

• Artz CP. Historical aspects of burn management. Surg Clin North Am. 1970;50:1193–1200.
   PubMed Web of Science ®Google Scholar
• Liu HF, Zhang F, Lineaweaver WC. History and advancement of burn treatments. Ann Plast Surg. 2017;78:S2–S8.
   PubMed Web of Science ®Google Scholar
• Majno G. The healing hand: man and wound in the ancient world. MA: HarvardUniversity Press Cambridge; 1975.
   Google Scholar
• Markatos K, Tzivra A, Tsoutsos S, et al. Ambroise pare (1510-1590) and his innovative work on the treatment of war injuries. Surg Innov. 2018;25:183–186.
   PubMed Web of Science ®Google Scholar
• Kirkpatrick JJ, Curtis B, Fitzgerald AM, et al. A modern translation and interpretation of the treatise on burns of Fabricius Hildanus (1560-1634). Br J Plast Surg. 1995;48:460–470.
   PubMedGoogle Scholar
• Kentish E. An essay on burns, principally upon those which happpen [sic] to workmen in mines from the explosions of inflammable air, (or hydrogen gas.). Newcastle,UK : G.G. and J. Robinson; 1797.
   Google Scholar
• Dickinson N. Remarks on burns and scalds, chiefly in reference to the principle of treatment at the time of their infliction. Suggested by a perusal of the last edition of ‘An essay on burns’, by Edward Kentish, M.D.J. UK: London; 1818.
   Google Scholar
• Dupuytren G. Causes, different degrees, complications, anatomical characters and treatment of burns. Clin Lect Surg. 1832;18:229–280.
   Google Scholar
• Curling TB. On acute ulceration of the duodenum in cases of burn. Med Chir Trans. 42:30–31.
   Google Scholar
• Reverdin J. De la greffe epidermique (Classic reprint). London¸UK: FB&C Ltd; 2017. ( 1872).
   Google Scholar
• Shirani KZ, Vaughan GM, Mason AD Jr., et al. Update on current therapeutic approaches in burns. Shock. 1996;5:4–16.
   PubMed Web of Science ®Google Scholar
• Jeschke MG, Kamolz L-P, Sjöberg F, et al. Handbook of burns volume 1: acute burn care. New York, NY: Springer Science & Business Media; 2012.
   Google Scholar
• Bull JP, Fisher AJ. A study of mortality in a burns unit: a revised estimate. Ann Surg. 1954;139:269–274.
   PubMed Web of Science ®Google Scholar
• Pruitt BA Jr., Goodwin CW, Mason ADJ. Epidemiological, emographic, and outcome characteristics of burn injury. In: Herndon DN, Saunders WB, editors. Total burn care. Philadelphia, PA: WB Saunders; 2002. p. 16–30.
   Google Scholar
• Barrow RE, Spies M, Barrow LN, et al. Influence of demographics and inhalation injury on burn mortality in children. Burns. 2004;30:72–77.
   PubMed Web of Science ®Google Scholar
• Saaiq M, Zaib S, Ahmad S. Early excision and grafting versus delayed excision and grafting of deep thermal burns up to 40% total body surface area: a comparison of outcome. Ann Burns Fire Disasters. 2012;25:143–147.
   PubMedGoogle Scholar
• Keshavarzi A, Ayaz M, Dehghankhalili M. Ultra-early versus early excision and grafting for thermal burns up to 60% total body surface area; a historical cohort study. Bull Emerg Trauma. 2016;4:197–201.
   PubMedGoogle Scholar
• Wang Y, Beekman J, Hew J, et al. Burn injury: challenges and advances in burn wound healing, infection, pain and scarring. Adv Drug Deliv Rev. 2018;123:3–17.
   PubMed Web of Science ®Google Scholar
• Smolle C, Cambiaso-Daniel J, Forbes AA, et al. Recent trends in burn epidemiology worldwide: a systematic review. Burns. 2017;43:249–257.
   PubMed Web of Science ®Google Scholar
• Peck M, Pressman MA. The correlation between burn mortality rates from fire and flame and economic status of countries. Burns. 2013;39:1054–1059.
   PubMed Web of Science ®Google Scholar
• World_Health_Organization. The global burden of disease: 2004 update. The Global Burden of Disease: 2004 Update. 2008.
   Google Scholar
• American_Burn_Association. National Burn Repository (2012 report). National Burn Repository (2012 report). 2012.
   Google Scholar
• Friedstat J, Brown DA, Levi B. Chemical, electrical, and radiation injuries. Clin Plast Surg. 2017;44:657–669.
   PubMed Web of Science ®Google Scholar
• Abdullahi A, Amini-Nik S, Jeschke MG. Animal models in burn research. Cell Mol Life Sci. 2014;71:3241–3255.
   PubMed Web of Science ®Google Scholar
• Shupp JW, Nasabzadeh TJ, Rosenthal DS, et al. A review of the local pathophysiologic bases of burn wound progression. J Burn Care Res. 2010;31:849–873.
   PubMed Web of Science ®Google Scholar
• Walker HL, Mason AD Jr. A standard animal burn. J Trauma. 1968;8:1049–1051.
   PubMed Web of Science ®Google Scholar
• Steinstraesser L, Trust G, Rittig A et al. Colistin-loaded silk membranes against wound infection with Pseudomonas aeruginosa. Plast Reconstr Surg. 2011;127:1838–1846.
   PubMed Web of Science ®Google Scholar
• Jones WG 2nd, Minei JP, Barber AE, et al. Bacterial translocation and intestinal atrophy after thermal injury and burn wound sepsis. Ann Surg. 1990;211:399–405.
   PubMed Web of Science ®Google Scholar
• Nakae H, Inaba H, Endo S. Usefulness of procalcitonin in Pseudomonas burn wound sepsis model. Tohoku J Exp Med. 1999;188:271–273.
   PubMed Web of Science ®Google Scholar
• Barnea Y, Carmeli Y, Kuzmenko B, et al. The establishment of a Pseudomonas aeruginosa-infected burn-wound sepsis model and the effect of imipenem treatment. Ann Plast Surg. 2006;56:674–679.
   PubMed Web of Science ®Google Scholar
• Fader RC, Nunez D, Unbehagen J, et al. Experimental candidiasis after thermal injury. Infect Immun. 1985;49:780–784.
   PubMed Web of Science ®Google Scholar
• Steinstraesser L, Tack BF, Waring AJ et al. Activity of novispirin G10 against Pseudomonas aeruginosa in vitro and in infected burns. Antimicrob Agents Chemother. 2002;46:1837–1844.
   PubMed Web of Science ®Google Scholar
• Jacobsen F, Mittler D, Hirsch T, et al. Transient cutaneous adenoviral gene therapy with human host defense peptide hCAP-18/LL-37 is effective for the treatment of burn wound infections. Gene Ther. 2005;12:1494–1502.
   PubMed Web of Science ®Google Scholar
• Bjornson AB, Bjornson HS, Lincoln NA, et al. Relative roles of burn injury, wound colonization, and wound infection in induction of alterations of complement function in a guinea pig model of burn injury. J Trauma. 1984;24:106–115.
   PubMed Web of Science ®Google Scholar
• Orenstein A, Klein D, Kopolovic J, et al. The use of porphyrins for eradication of Staphylococcus aureus in burn wound infections. FEMS Immunol Med Microbiol. 1997;19:307–314.
   PubMed Web of Science ®Google Scholar
• Stieritz DD, Holder IA. Experimental studies of the pathogenesis of infections due to Pseudomonas aeruginosa: description of a burned mouse model. J Infect Dis. 1975;131:688–691.
   PubMed Web of Science ®Google Scholar
• Katakura T, Yoshida T, Kobayashi M, et al. Immunological control of methicillin-resistant Staphylococcus aureus (MRSA) infection in an immunodeficient murine model of thermal injuries. Clin Exp Immunol. 2005;142:419–425.
   PubMed Web of Science ®Google Scholar
• Manafi A, Kohanteb J, Mehrabani D, et al. Active immunization using exotoxin A confers protection against Pseudomonas aeruginosa infection in a mouse burn model. BMC Microbiol. 2009;9:23.
   PubMed Web of Science ®Google Scholar
• Kumari S, Harjai K, Chhibber S. Topical treatment of Klebsiella pneumoniae B5055 induced burn wound infection in mice using natural products. J Infect Dev Ctries. 2010;4:367–377.
   PubMed Web of Science ®Google Scholar
• Gurfinkel R, Singer AJ, Cagnano E, et al. Development of a novel animal burn model using radiant heat in rats and swine. Acad Emerg Med. 2010;17:514–520.
   PubMed Web of Science ®Google Scholar
• Summer GJ, Puntillo KA, Miaskowski C, et al. TrkA and PKC-epsilon in thermal burn-induced mechanical hyperalgesia in the rat. J Pain. 2006;7:884–891.
   PubMed Web of Science ®Google Scholar
• Hart DW, Wolf SE, Mlcak R, et al. Persistence of muscle catabolism after severe burn. Surgery. 2000;128:312–319.
   PubMed Web of Science ®Google Scholar
• Williams FN, Herndon DN. Metabolic and endocrine considerations after burn injury. Clin Plast Surg. 2017;44:541–553.
   PubMed Web of Science ®Google Scholar
• Jeschke MG, Chinkes DL, Finnerty CC, et al. Pathophysiologic response to severe burn injury. Ann Surg. 2008;248:387–401.
   PubMed Web of Science ®Google Scholar
• Williams FN, Herndon DN, Hawkins HK, et al. The leading causes of death after burn injury in a single pediatric burn center. Crit Care. 2009;13:R183.
   PubMed Web of Science ®Google Scholar
• Gauglitz GG, Williams FN, Herndon DN, et al. Burns: where are we standing with propranolol, oxandrolone, recombinant human growth hormone, and the new incretin analogs? Curr Opin Clin Nutr Metab Care. 2011;14:176–181.
   PubMed Web of Science ®Google Scholar
• Gauglitz GG, Herndon DN, Kulp GA, et al. Abnormal insulin sensitivity persists up to three years in pediatric patients post-burn. J Clin Endocrinol Metab. 2009;94:1656–1664.
   PubMed Web of Science ®Google Scholar
• Abdullahi A, Jeschke MG. Nutrition and anabolic pharmacotherapies in the care of burn patients. Nutr Clin Pract. 2014;29:621–630.
   PubMed Web of Science ®Google Scholar
• Kulp GA, Tilton RG, Herndon DN, et al. Hyperglycemia exacerbates burn-induced liver inflammation via noncanonical nuclear factor-kappaB pathway activation. Mol Med. 2012;18:948–956.
   PubMed Web of Science ®Google Scholar
• Barret JP, Jeschke MG, Herndon DN. Fatty infiltration of the liver in severely burned pediatric patients: autopsy findings and clinical implications. J Trauma. 2001;51:736–739.
   PubMedGoogle Scholar
• Prelack K, Dylewski M, Sheridan RL. Practical guidelines for nutritional management of burn injury and recovery. Burns. 2007;33:14–24.
   PubMed Web of Science ®Google Scholar
• Al-Mousawi AM, Williams FN, Mlcak RP, et al. Effects of exercise training on resting energy expenditure and lean mass during pediatric burn rehabilitation. J Burn Care Res. 2010;31:400–408.
   PubMed Web of Science ®Google Scholar
• Branski LK, Herndon DN, Barrow RE, et al. Randomized controlled trial to determine the efficacy of long-term growth hormone treatment in severely burned children. Ann Surg. 2009;250:514–523.
   PubMed Web of Science ®Google Scholar
• Jeschke MG, Herndon DN, Barrow RE. Insulin-like growth factor I in combination with insulin-like growth factor binding protein 3 affects the hepatic acute phase response and hepatic morphology in thermally injured rats. Ann Surg. 2000;231:408–416.
   PubMed Web of Science ®Google Scholar
• Spies M, Wolf SE, Barrow RE, et al. Modulation of types I and II acute phase reactants with insulin-like growth factor-1/binding protein-3 complex in severely burned children. Crit Care Med. 2002;30:83–88.
   PubMed Web of Science ®Google Scholar
• Pidcoke HF, Wade CE, Wolf SE. Insulin and the burned patient. Crit Care Med. 2007;35:S524–S530.
   PubMed Web of Science ®Google Scholar
• Finney SJ, Zekveld C, Elia A, et al. Glucose control and mortality in critically ill patients. JAMA. 2003;290:2041–2047.
   PubMed Web of Science ®Google Scholar
• Brunkhorst FM, Engel C, Bloos F, et al. Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med. 2008;358:125–139.
   PubMed Web of Science ®Google Scholar
• Jeschke MG, Finnerty CC, Suman OE, et al. The effect of oxandrolone on the endocrinologic, inflammatory, and hypermetabolic responses during the acute phase postburn. Ann Surg. 2007;246: 351–360. discussion 360-352.
   PubMed Web of Science ®Google Scholar
• Wolf SE, Edelman LS, Kemalyan N, et al. Effects of oxandrolone on outcome measures in the severely burned: a multicenter prospective randomized double-blind trial. J Burn Care Res. 2006;27:131–139. discussion 140-131.
   PubMed Web of Science ®Google Scholar
• Przkora R, Herndon DN, Suman OE. The effects of oxandrolone and exercise on muscle mass and function in children with severe burns. Pediatrics. 2007;119:e109–e116.
   PubMed Web of Science ®Google Scholar
• Sirtori CR, Pasik C. Re-evaluation of a biguanide, metformin: mechanism of action and tolerability. Pharmacol Res. 1994;30:187–228.
   PubMed Web of Science ®Google Scholar
• Gore DC, Wolf SE, Herndon DN, et al. Metformin blunts stress-induced hyperglycemia after thermal injury. J Trauma. 2003;54:555–561.
   PubMedGoogle Scholar
• Gore DC, Herndon DN, Wolfe RR. Comparison of peripheral metabolic effects of insulin and metformin following severe burn injury. J Trauma. 2005;59: 316–322. discussion 322-313.
   PubMedGoogle Scholar
• Angioi A, Cabiddu G, Conti M, et al. Metformin associated lactic acidosis: a case series of 28 patients treated with sustained low-efficiency dialysis (SLED) and long-term follow-up. BMC Nephrol. 2018;19:77.
   PubMed Web of Science ®Google Scholar
• Flores O, Stockton K, Roberts JA, et al. The efficacy and safety of adrenergic blockade after burn injury: a systematic review and meta-analysis. J Trauma Acute Care Surg. 2016;80:146–155.
   PubMed Web of Science ®Google Scholar
• Williams FN, Herndon DN, Kulp GA, et al. Propranolol decreases cardiac work in a dose-dependent manner in severely burned children. Surgery. 2011;149:231–239.
   PubMed Web of Science ®Google Scholar
• Chao T, Porter C, Herndon DN, et al. Propranolol and oxandrolone therapy accelerated muscle recovery in burned children. Med Sci Sports Exerc. 2018 Mar;50(3):427–435.
   PubMed Web of Science ®Google Scholar
• Andersen A, Lund A, Knop FK, et al. Glucagon-like peptide 1 in health and disease. Nat Rev Endocrinol. 2018 Jul;14(7):390–403.
   PubMed Web of Science ®Google Scholar
• Shen CA, Fagan S, Fischman AJ, et al. Effects of glucagon-like peptide 1 on glycemia control and its metabolic consequence after severe thermal injury–studies in an animal model. Surgery. 2011;149:635–644.
   PubMed Web of Science ®Google Scholar
• Gupta V. Glucagon-like peptide-1 analogues: an overview. Indian J Endocrinol Metab. 2013;17:413–421.
   PubMedGoogle Scholar
• Htike ZZ, Zaccardi F, Papamargaritis D, et al. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a systematic review and mixed-treatment comparison analysis. Diabetes Obes Metab. 2017;19:524–536.
   PubMed Web of Science ®Google Scholar
• Zhao D, Ma L, Shen C, et al. Long-lasting glucagon-like peptide 1 analogue exendin-4 ameliorates the secretory and synthetic function of islets isolated from severely scalded rats. J Burn Care Res. 2018 Jun 13;39(4):545–554.
   PubMed Web of Science ®Google Scholar
• Jia YL, Sun SJ, Chen JH, et al. SS31, a small molecule antioxidant peptide, attenuates beta-amyloid elevation, mitochondrial/synaptic deterioration and cognitive deficit in SAMP8 mice. Curr Alzheimer Res. 2016;13:297–306.
   PubMed Web of Science ®Google Scholar
• Calkins MJ, Manczak M, Reddy PH. Mitochondria-targeted antioxidant SS31 prevents amyloid beta-induced mitochondrial abnormalities and synaptic degeneration in alzheimer’s disease. Pharmaceuticals (Basel). 2012;5:1103–1119.
   PubMedGoogle Scholar
• Carter EA, Bonab AA, Goverman J, et al. Evaluation of the antioxidant peptide SS31 for treatment of burn-induced insulin resistance. Int J Mol Med. 2011;28:589–594.
   PubMed Web of Science ®Google Scholar
• Gupta K, Mehrotra M, Kumar P, et al. Smoke inhalation injury: etiopathogenesis, diagnosis, and management. Indian J Crit Care Med. 2018;22:180–188.
   PubMed Web of Science ®Google Scholar
• Einhorn IN. Physiological and toxicological aspects of smoke produced during the combustion of polymeric materials. Environ Health Perspect. 1975;11:163–189.
   PubMedGoogle Scholar
• Palmieri TL, Enkhbaatar P, Sheridan R, et al. Studies of inhaled agents in inhalation injury. J Burn Care Res. 2009;30:169–171.
   PubMed Web of Science ®Google Scholar
• Yim RP, Koumbourlis AC. Tolerance & resistance to beta(2)-agonist bronchodilators. Paediatr Respir Rev. 2013;14:195–198.
   PubMed Web of Science ®Google Scholar
• Palmieri TL, Enkhbaatar P, Bayliss R, et al. Continuous nebulized albuterol attenuates acute lung injury in an ovine model of combined burn and smoke inhalation. Crit Care Med. 2006;34:1719–1724.
   PubMed Web of Science ®Google Scholar
• Roux E, Molimard M, Savineau JP, et al. Muscarinic stimulation of airway smooth muscle cells. Gen Pharmacol. 1998;31:349–356.
   PubMedGoogle Scholar
• Jonkam C, Zhu Y, Jacob S, et al. Muscarinic receptor antagonist therapy improves acute pulmonary dysfunction after smoke inhalation injury in sheep. Crit Care Med. 2010;38:2339–2344.
   PubMed Web of Science ®Google Scholar
• Lopez E, Fujiwara O, Lima-Lopez F, et al. Nebulized epinephrine limits pulmonary vascular hyperpermeability to water and protein in ovine with burn and smoke inhalation injury. Crit Care Med. 2016;44:e89–e96.
   PubMed Web of Science ®Google Scholar
• Foncerrada G, Lima F, Clayton RP, et al. Safety of nebulized epinephrine in smoke inhalation injury. J Burn Care Res. 2017;38:396–402.
   PubMed Web of Science ®Google Scholar
• Csontos C, Rezman B, Foldi V, et al. Effect of N-acetylcysteine treatment on oxidative stress and inflammation after severe burn. Burns. 2012;38:428–437.
   PubMed Web of Science ®Google Scholar
• Miller AC, Elamin EM, Suffredini AF. Inhaled anticoagulation regimens for the treatment of smoke inhalation-associated acute lung injury: a systematic review. Crit Care Med. 2014;42:413–419.
   PubMed Web of Science ®Google Scholar
• Enkhbaatar P, Cox RA, Traber LD, et al. Aerosolized anticoagulants ameliorate acute lung injury in sheep after exposure to burn and smoke inhalation. Crit Care Med. 2007;35:2805–2810.
   PubMed Web of Science ®Google Scholar
• Mcginn KA, Weigartz K, Lintner A, et al. Nebulized heparin with N-Acetylcysteine and albuterol reduces duration of mechanical ventilation in patients with inhalation injury. J Pharm Pract. 2017 Jan 1:897190017747143. doi: 10.1177/0897190017747143. [Epub ahead of print]. PMID: 29233052.
   PubMedGoogle Scholar
• Schmauss D, Rezaeian F, Finck T, et al. Treatment of secondary burn wound progression in contact burns-a systematic review of experimental approaches. J Burn Care Res. 2015;36:e176–e189.
   PubMed Web of Science ®Google Scholar
• Salibian AA, Rosario ATD, Severo L, et al. Current concepts on burn wound conversion-A review of recent advances in understanding the secondary progressions of burns. Burns. 2016;42:1025–1035.
   PubMed Web of Science ®Google Scholar
• Rocha J, Eduardo-Figueira M, Barateiro A, et al. Erythropoietin reduces acute lung injury and multiple organ failure/dysfunction associated to a scald-burn inflammatory injury in the rat. Inflammation. 2015;38:312–326.
   PubMed Web of Science ®Google Scholar
• Tobalem M, Harder Y, Schuster T, et al. Erythropoietin in the prevention of experimental burn progression. Br J Surg. 2012;99:1295–1303.
   PubMed Web of Science ®Google Scholar
• Tobalem M, Harder Y, Rezaeian F, et al. Secondary burn progression decreased by erythropoietin. Crit Care Med. 2013;41:963–971.
   PubMed Web of Science ®Google Scholar
• Mcmillen MA. Endothelin plasma levels in burn patients. Arch Surg. 2001;136:1084.
   PubMedGoogle Scholar
• Battal MN, Hata Y, Matsuka K, et al. Reduction of progressive burn injury by using a new nonselective endothelin-A and endothelin-B receptor antagonist, TAK-044: an experimental study in rats. Plast Reconstr Surg. 1997;99:1610–1619.
   PubMed Web of Science ®Google Scholar
• Battal MN, Hata Y, Matsuka K, et al. Reduction of progressive burn injury by a stable prostaglandin I2 analogue, beraprost sodium (Procylin): an experimental study in rats. Burns. 1996;22:531–538.
   PubMed Web of Science ®Google Scholar
• Hunter RL, Luo AZ, Zhang R, et al. Poloxamer 188 inhibition of ischemia/reperfusion injury: evidence for a novel anti-adhesive mechanism. Ann Clin Lab Sci. 2010;40:115–125.
   PubMed Web of Science ®Google Scholar
• Baskaran H, Toner M, Yarmush ML, et al. Poloxamer-188 improves capillary blood flow and tissue viability in a cutaneous burn wound. J Surg Res. 2001;101:56–61.
   PubMed Web of Science ®Google Scholar
• Yuhua S, Ligen L, Jiake C, et al. Effect of Poloxamer 188 on deepening of deep second-degree burn wounds in the early stage. Burns. 2012;38:95–101.
   PubMed Web of Science ®Google Scholar
• Isik S, Sahin U, Ilgan S, et al. Saving the zone of stasis in burns with recombinant tissue-type plasminogen activator (r-tPA): an experimental study in rats. Burns. 1998;24:217–223.
   PubMed Web of Science ®Google Scholar
• Meyerholz DK, Piester TL, Mcnamara AR, et al. Pharmacologic modification to resuscitation fluid after thermal injury–is drotrecogin alfa the answer to arrest burn depth progression? J Trauma. 2009;67:996–1003.
   PubMedGoogle Scholar
• Undas A, Brummel-Ziedins KE, Mann KG. Anticoagulant effects of statins and their clinical implications. Thromb Haemost. 2014;111:392–400.
   PubMed Web of Science ®Google Scholar
• Uygur F, Evinc R, Urhan M, et al. Salvaging the zone of stasis by simvastatin: an experimental study in rats. J Burn Care Res. 2009;30:872–879.
   PubMed Web of Science ®Google Scholar
• Dahiya P. Burns as a model of SIRS. Front Biosci (Landmark Ed). 2009;14:4962–4967.
   PubMed Web of Science ®Google Scholar
• Friedl HP, Till GO, Trentz O, et al. Roles of histamine, complement and xanthine oxidase in thermal injury of skin. Am J Pathol. 1989;135:203–217.
   PubMed Web of Science ®Google Scholar
• Ward PA, Till GO. Pathophysiologic events related to thermal injury of skin. J Trauma. 1990;30:S75–S79.
   PubMedGoogle Scholar
• Endo S, Inada K, Yamada Y, et al. Plasma tumour necrosis factor-alpha (TNF-alpha) levels in patients with burns. Burns. 1993;19:124–127.
   PubMed Web of Science ®Google Scholar
• Moore FD Jr., Davis C, Rodrick M, et al. Neutrophil activation in thermal injury as assessed by increased expression of complement receptors. N Engl J Med. 1986;314:948–953.
   PubMed Web of Science ®Google Scholar
• Singer AJ, Mcclain SA, Hacht G, et al. Semapimod reduces the depth of injury resulting in enhanced re-epithelialization of partial-thickness burns in swine. J Burn Care Res. 2006;27:40–49.
   PubMed Web of Science ®Google Scholar
• Sun LT, Friedrich E, Heuslein JL, et al. Reduction of burn progression with topical delivery of (antitumor necrosis factor-alpha)-hyaluronic acid conjugates. Wound Repair Regen. 2012;20:563–572.
   PubMed Web of Science ®Google Scholar
• Bucky LP, Vedder NB, Hong HZ, et al. Reduction of burn injury by inhibiting CD18-mediated leukocyte adherence in rabbits. Plast Reconstr Surg. 1994;93:1473–1480.
   PubMed Web of Science ®Google Scholar
• Choi M, Rabb H, Arnaout MA, et al. Preventing the infiltration of leukocytes by monoclonal antibody blocks the development of progressive ischemia in rat burns. Plast Reconstr Surg. 1995;96: 1177–1185. discussion 1186-1177.
   PubMedGoogle Scholar
• Mileski W, Borgstrom D, Lightfoot E, et al. Inhibition of leukocyte-endothelial adherence following thermal injury. J Surg Res. 1992;52:334–339.
   PubMed Web of Science ®Google Scholar
• Lin CF, Young KC, Bai CH, et al. Rosiglitazone regulates anti-inflammation and growth inhibition via PTEN. Biomed Res Int. 2014;787924:2014.
   Google Scholar
• Taira BR, Singer AJ, Mcclain SA, et al. Rosiglitazone, a PPAR-gamma ligand, reduces burn progression in rats. J Burn Care Res. 2009;30:499–504.
   PubMed Web of Science ®Google Scholar
• Singer AJ, Taira BR, Lin F, et al. Curcumin reduces injury progression in a rat comb burn model. J Burn Care Res. 2011;32:135–142.
   PubMed Web of Science ®Google Scholar
• Jha A, Mohapatra PP, Alharbi SA, et al. Curcumin: not so spicy after all. Mini Rev Med Chem. 2017;17:1425–1434.
   PubMed Web of Science ®Google Scholar
• Clark WM, Hazel JS, Coull BM. Lazaroids. CNS pharmacology and current research. Drugs. 1995;50:971–983.
   PubMed Web of Science ®Google Scholar
• Choi M, Ehrlich HP. U75412E, a lazaroid, prevents progressive burn ischemia in a rat burn model. Am J Pathol. 1993;142:519–528.
   PubMed Web of Science ®Google Scholar
• Deniz M, Borman H, Seyhan T, et al. An effective antioxidant drug on prevention of the necrosis of zone of stasis: N-acetylcysteine. Burns. 2013;39:320–325.
   PubMed Web of Science ®Google Scholar
• Wang CZ, Ayadi AE, Goswamy J, et al. Topically applied metal chelator reduces thermal injury progression in a rat model of brass comb burn. Burns. 2015;41:1775–1787.
   PubMed Web of Science ®Google Scholar
• Vorauer-Uhl K, Furnschlief E, Wagner A, et al. Reepithelialization of experimental scalds effected by topically applied superoxide dismutase: controlled animal studies. Wound Repair Regen. 2002;10:366–371.
   PubMed Web of Science ®Google Scholar
• Shalom A, Kramer E, Westreich M. Protective effect of human recombinant copper-zinc superoxide dismutase (hr-cuznsod) on intermediate burn survival in rats. Ann Burns Fire Disasters. 2008;21:16–19.
   PubMedGoogle Scholar
• Shalom A, Kramer E, Westreich M. Protective effect of human recombinant copper-zinc superoxide dismutase on zone of stasis survival in burns in rats. Ann Plast Surg. 2011;66:607–609.
   PubMed Web of Science ®Google Scholar
• Dunlop EA, Tee AR. mTOR and autophagy: a dynamic relationship governed by nutrients and energy. Semin Cell Dev Biol. 2014;36:121–129.
   PubMed Web of Science ®Google Scholar
• Xiao M, Li L, Hu Q, et al. Rapamycin reduces burn wound progression by enhancing autophagy in deep second-degree burn in rats. Wound Repair Regen. 2013;21:852–859.
   PubMed Web of Science ®Google Scholar
• Appleby BS, Nacopoulos D, Milano N, et al. A review: treatment of Alzheimer’s disease discovered in repurposed agents. Dement Geriatr Cogn Disord. 2013;35:1–22.
   PubMed Web of Science ®Google Scholar
• Wu HM, Lee CG, Hwang SJ, et al. Mitigation of carbon tetrachloride-induced hepatic injury by methylene blue, a repurposed drug, is mediated by dual inhibition of GSK3beta downstream of PKA. Br J Pharmacol. 2014;171:2790–2802.
   PubMed Web of Science ®Google Scholar
• Shin JY, Kim SJ, Kim DK, et al. Fundamental characteristics of deep-UV light-emitting diodes and their application to control foodborne pathogens. Appl Environ Microbiol. 2016;82:2–10.
   PubMed Web of Science ®Google Scholar
• Rosique MJ, Rosique RG, Faria FM, et al. Methylene blue reduces progression of burn and increases skin survival in an experimental rat model. Burns. 2017;43:1702–1708.
   PubMed Web of Science ®Google Scholar
• Malykh AG, Sadaie MR. Piracetam and piracetam-like drugs: from basic science to novel clinical applications to CNS disorders. Drugs. 2010;70:287–312.
   PubMed Web of Science ®Google Scholar
• Germonpre P, Reper P, Vanderkelen A. Hyperbaric oxygen therapy and piracetam decrease the early extension of deep partial-thickness burns. Burns. 1996;22:468–473.
   PubMed Web of Science ®Google Scholar
• Sari E, Dincel GC. Effect of piracetam and nimodipine on full-thickness skin burns in rabbits. Int Wound J. 2016;13:563–571.
   PubMed Web of Science ®Google Scholar
• Morykwas MJ, Simpson J, Punger K, et al. Vacuum-assisted closure: state of basic research and physiologic foundation. Plast Reconstr Surg. 2006;117:121S–126S.
   PubMed Web of Science ®Google Scholar
• Morykwas MJ, David LR, Schneider AM, et al. Use of subatmospheric pressure to prevent progression of partial-thickness burns in a swine model. J Burn Care Rehabil. 1999;20:15–21.
   PubMedGoogle Scholar
• Dauwe PB, Pulikkottil BJ, Lavery L, et al. Does hyperbaric oxygen therapy work in facilitating acute wound healing: a systematic review. Plast Reconstr Surg. 2014;133:208e–215e.
   PubMed Web of Science ®Google Scholar
• Turkaslan T, Yogun N, Cimsit M, et al. Is HBOT treatment effective in recovering zone of stasis? An experimental immunohistochemical study. Burns. 2010;36:539–544.
   PubMed Web of Science ®Google Scholar
• De Freitas LF, Hamblin MR. Proposed mechanisms of photobiomodulation or low-level light therapy. IEEE J Sel Top Quantum Electron. 2016;22.
   PubMed Web of Science ®Google Scholar
• Rathnakar B, Rao BS, Prabhu V, et al. Photo-biomodulatory response of low-power laser irradiation on burn tissue repair in mice. Lasers Med Sci. 2016;31:1741–1750.
   PubMed Web of Science ®Google Scholar
• Yadav A, Gupta A, Keshri GK, et al. Photobiomodulatory effects of superpulsed 904nm laser therapy on bioenergetics status in burn wound healing. J Photochem Photobiol B. 2016;162:77–85.
   PubMed Web of Science ®Google Scholar
• Wasiak J, Cleland H. Burns: dressings. BMJ Clin Evid. 2015 Jul 14;2015. pii: 1903. Review. PMID: 26173045.
   PubMedGoogle Scholar
• Zarrintaj P, Moghaddam AS, Manouchehri S, et al. Can regenerative medicine and nanotechnology combine to heal wounds? The search for the ideal wound dressing. Nanomedicine. 2017;12:2403–2422.
   PubMed Web of Science ®Google Scholar
• Gaucher S, Duchange N, Jarraya M, et al. Severe adult burn survivors. What information about skin allografts? Cell Tissue Bank. 2013;14:505–510.
   PubMed Web of Science ®Google Scholar
• Hermans MH. Porcine xenografts vs. (cryopreserved) allografts in the management of partial thickness burns: is there a clinical difference? Burns. 2014;40:408–415.
   PubMed Web of Science ®Google Scholar
• Tenenhaus M. The use of dehydrated human amnion/chorion membranes in the treatment of burns and complex wounds: current and future applications. Ann Plast Surg. 2017;78:S11–S13.
   PubMed Web of Science ®Google Scholar
• Gierek M, Kawecki M, Mikus K, et al. Biological dressings as a substitutes of the skin in the treatment of burn wounds. Pol Przegl Chir. 2013;85:354–359.
   PubMedGoogle Scholar
• Wasiak J, Cleland H, Campbell F, et al. Dressings for superficial and partial thickness burns. Cochrane Database Syst Rev. 2013 Mar 28;(3):CD002106. doi: 10.1002/14651858.CD002106.pub4. Review.PMID: 23543513.
   PubMed Web of Science ®Google Scholar
• Carta T, Gawaziuk JP, Diaz-Abele J, et al. Properties of an ideal burn dressing: a survey of burn survivors and front-line burn healthcare providers. Burns. 2018 Oct 13. pii: S0305–4179;(18)30843-X. doi: 10.1016/j.burns.2018.09.021. [Epub ahead of print]
   Google Scholar
• Dai T, Huang YY, Sharma SK, et al. Topical antimicrobials for burn wound infections. Recent Pat Antiinfect Drug Discov. 2010;5:124–151.
   PubMedGoogle Scholar
• Jahromi M, Zangabad PS, Basri SMM, et al. Nanomedicine and advanced technologies for burns: preventing infection and facilitating wound healing. Adv Drug Deliv Rev. 2018 Jan 1;123:33–64.
   Web of Science ®Google Scholar
• Church D, Elsayed S, Reid O, et al. Burn wound infections. Clin Microbiol Rev. 2006;19:403–434.
   PubMed Web of Science ®Google Scholar
• Gravante G, Delogu D, Sconocchia G. “Systemic apoptotic response” after thermal burns. Apoptosis. 2007;12:259–270.
   PubMed Web of Science ®Google Scholar
• Zavlin D, Chegireddy V, Boukovalas S, et al. Multi-institutional analysis of independent predictors for burn mortality in the United States. Burns Trauma. 2018;6:24.
   PubMed Web of Science ®Google Scholar
• Honari S. Topical therapies and antimicrobials in the management of burn wounds. Crit Care Nurs Clin North Am. 2004;16:1–11.
   PubMedGoogle Scholar
• Glasser JS, Guymon CH, Mende K, et al. Activity of topical antimicrobial agents against multidrug-resistant bacteria recovered from burn patients. Burns. 2010;36:1172–1184.
   PubMed Web of Science ®Google Scholar
• Marx DE, Barillo DJ. Silver in medicine: the basic science. Burns. 2014;40(Suppl 1):S9–S18.
   PubMedGoogle Scholar
• Heyneman A, Hoeksema H, Vandekerckhove D, et al. The role of silver sulphadiazine in the conservative treatment of partial thickness burn wounds: A systematic review. Burns. 2016;42:1377–1386.
   PubMed Web of Science ®Google Scholar
• Mofazzal Jahromi MA, Sahandi Zangabad P, Moosavi Basri SM, et al. Nanomedicine and advanced technologies for burns: preventing infection and facilitating wound healing. Adv Drug Deliv Rev. 2018;123:33–64.
   PubMed Web of Science ®Google Scholar
• Grützner V, Unger RE, Baier G, et al. Enzyme-responsive nanocomposites for wound infection prophylaxis in burn management: in vitro evaluation of their compatibility with healing processes. Int J Nanomedicine. 2015;10:4111.
   PubMed Web of Science ®Google Scholar
• Hathaway H, Alves DR, Bean J, et al. Poly(N-isopropylacrylamide-co-allylamine) (PNIPAM-co-ALA) nanospheres for the thermally triggered release of Bacteriophage K. Eur J Pharm Biopharm. 2015;96:437–441.
   PubMed Web of Science ®Google Scholar
• Öhlknecht C, Tegl G, Beer B, et al. Cellobiose dehydrogenase and chitosan-based lysozyme responsive materials for antimicrobial wound treatment. Biotechnol Bioeng. 2017;114:416–422.
   PubMed Web of Science ®Google Scholar
• Yin R, Dai T, Avci P, et al. Light based anti-infectives: ultraviolet C irradiation, photodynamic therapy, blue light, and beyond. Curr Opin Pharmacol. 2013 Oct;13(5):731–762.
   PubMed Web of Science ®Google Scholar
• Hamblin MR. Potentiation of antimicrobial photodynamic inactivation by inorganic salts. Expert Rev Anti Infect Ther. 2017 Nov;15(11):1059–1069.
   PubMed Web of Science ®Google Scholar
• Dai T, Gupta A, Huang YY, et al. Blue light rescues mice from potentially fatal Pseudomonas aeruginosa burn infection: efficacy, safety, and mechanism of action. Antimicrob Agents Chemother. 2013 Mar;57(3):1238–1245.
   Google Scholar
• Dai T, Kharkwal GB, Zhao J, et al. Ultraviolet-C light for treatment of Candida albicans burn infection in mice. Photochem Photobiol. 2011;87:342–349.
   PubMed Web of Science ®Google Scholar
• Dai T, Murray CK, Vrahas MS, et al. Ultraviolet C light for Acinetobacter baumannii wound infections in mice: potential use for battlefield wound decontamination? J Trauma Acute Care Surg. 2012;73:661–667.
   PubMed Web of Science ®Google Scholar
• Sennett R, Wang Z, Rezza A, et al. An integrated transcriptome atlas of embryonic hair follicle progenitors, their niche, and the developing skin. Dev Cell. 2015;34:577–591.
   PubMed Web of Science ®Google Scholar
• Plikus MV, Van Spyk EN, Pham K, et al. The circadian clock in skin implications for adult stem cells, tissue regeneration, cancer, aging, and immunity. J Biol Rhythms. 2015;30:163–182.
   PubMed Web of Science ®Google Scholar
• Streckfuss-Bömeke K, Wolf F, Azizian A, et al. Comparative study of human-induced pluripotent stem cells derived from bone marrow cells, hair keratinocytes, and skin fibroblasts. Eur Heart J. 2013;34:2618–2629.
   PubMed Web of Science ®Google Scholar
• Murphy MB, Moncivais K, Caplan AI. Mesenchymal stem cells: environmentally responsive therapeutics for regenerative medicine. Exp Mol Med. 2013;45:e54.
   PubMed Web of Science ®Google Scholar
• Condé-Green A, Marano AA, Lee ES, et al. Fat grafting and adipose-derived regenerative cells in burn wound healing and scarring: a systematic review of the literature. Plast Reconstr Surg. 2016;137:302–312.
   PubMed Web of Science ®Google Scholar
• Antonyshyn JA, Fitzpatrick LE. Stem cell and stem cell-derived molecular therapies to enhance dermal wound healing. In: Ankur Singh, Akhilesh K. Gaharwar, editors. Microscale technologies for cell engineering. Basel, Switzerland: Springer International Publishing; 2016. p. 113–141.
   Google Scholar
• Kumar A, Mohanty S, Nandy SB, et al. Hair & skin derived progenitor cells: in search of a candidate cell for regenerative medicine. Indian J Med Res. 2016;143:175.
   PubMed Web of Science ®Google Scholar
• Hocking AM, Gibran NS. Mesenchymal stem cells: paracrine signaling and differentiation during cutaneous wound repair. Exp Cell Res. 2010;316:2213–2219.
   PubMed Web of Science ®Google Scholar
• Blais M, Parenteau-Bareil R, Cadau S, et al. Concise review: tissue-engineered skin and nerve regeneration in burn treatment. Stem Cells Transl Med. 2013;2:545–551.
   PubMed Web of Science ®Google Scholar
• Watt SM, Pleat JM. Stem cells, niches and scaffolds: applications to burns and wound care. Adv Drug Deliv Rev. 2018;123:82–106.
   PubMed Web of Science ®Google Scholar
• Friedstat JS, Hultman CS. Hypertrophic burn scar management: what does the evidence show? A systematic review of randomized controlled trials. Ann Plast Surg. 2014;72:S198–S201.
   PubMed Web of Science ®Google Scholar
• Rabello FB, Souza CD, Farina Junior JA. Update on hypertrophic scar treatment. Clinics (Sao Paulo). 2014;69:565–573.
   PubMed Web of Science ®Google Scholar
• Adzick NS, Lorenz HP. Cells, matrix, growth factors, and the surgeon. The biology of scarless fetal wound repair. Ann Surg. 1994;220:10–18.
   PubMed Web of Science ®Google Scholar
• Dang C, Ting K, Soo C, et al. Fetal wound healing current perspectives. Clin Plast Surg. 2003;30:13–23.
   PubMed Web of Science ®Google Scholar
• Gary-Bobo M, Nirde P, Jeanjean A, et al. Mannose 6-phosphate receptor targeting and its applications in human diseases. Curr Med Chem. 2007;14:2945–2953.
   PubMed Web of Science ®Google Scholar
• Dienus K, Bayat A, Gilmore BF, et al. Increased expression of fibroblast activation protein-alpha in keloid fibroblasts: implications for development of a novel treatment option. Arch Dermatol Res. 2010;302:725–731.
   PubMed Web of Science ®Google Scholar
• Roberts AB, Russo A, Felici A, et al. Smad3: a key player in pathogenetic mechanisms dependent on TGF-beta. Ann N Y Acad Sci. 2003;995:1–10.
   PubMed Web of Science ®Google Scholar
• Liu L, Liu X, Ren X, et al. Smad2 and Smad3 have differential sensitivity in relaying TGFbeta signaling and inversely regulate early lineage specification. Sci Rep. 2016;6:21602.
   PubMed Web of Science ®Google Scholar
• Hu HH, Chen DQ, Wang YN, et al. New insights into TGF-beta/Smad signaling in tissue fibrosis. Chem Biol Interact. 2018;292:76–83.
   PubMed Web of Science ®Google Scholar
• Wang Z, Gao Z, Shi Y, et al. Inhibition of Smad3 expression decreases collagen synthesis in keloid disease fibroblasts. J Plast Reconstr Aesthet Surg. 2007;60:1193–1199.
   PubMed Web of Science ®Google Scholar
• Arno AI, Gauglitz GG, Barret JP, et al. New molecular medicine-based scar management strategies. Burns. 2014;40:539–551.
   PubMed Web of Science ®Google Scholar
• Mcgaha TL, Phelps RG, Spiera H, et al. Halofuginone, an inhibitor of type-I collagen synthesis and skin sclerosis, blocks transforming-growth-factor-beta-mediated Smad3 activation in fibroblasts. J Invest Dermatol. 2002;118:461–470.
   PubMed Web of Science ®Google Scholar
• Mccormick LL, Zhang Y, Tootell E, et al. Anti-TGF-beta treatment prevents skin and lung fibrosis in murine sclerodermatous graft-versus-host disease: a model for human scleroderma. J Immunol. 1999;163:5693–5699.
   PubMed Web of Science ®Google Scholar
• Mehta M, Branford OA, Rolfe KJ. The evidence for natural therapeutics as potential anti-scarring agents in burn-related scarring. Burns Trauma. 2016;4:15.
   PubMed Web of Science ®Google Scholar
• Horton JA, Li F, Chung EJ, et al. Quercetin inhibits radiation-induced skin fibrosis. Radiat Res. 2013;180:205–215.
   PubMed Web of Science ®Google Scholar
• Santiago B, Gutierrez-Canas I, Dotor J, et al. Topical application of a peptide inhibitor of transforming growth factor-beta1 ameliorates bleomycin-induced skin fibrosis. J Invest Dermatol. 2005;125:450–455.
   PubMed Web of Science ®Google Scholar
• San-Martin A, Dotor J, Martinez F, et al. Effect of the inhibitor peptide of the transforming growth factor beta (p144) in a new silicone pericapsular fibrotic model in pigs. Aesthetic Plast Surg. 2010;34:430–437.
   PubMed Web of Science ®Google Scholar
• Tang B, Zhu B, Liang Y, et al. Asiaticoside suppresses collagen expression and TGF-beta/Smad signaling through inducing Smad7 and inhibiting TGF-betaRI and TGF-betaRII in keloid fibroblasts. Arch Dermatol Res. 2011;303:563–572.
   PubMed Web of Science ®Google Scholar
• Zunwen L, Shizhen Z, Dewu L, et al. Effect of tetrandrine on the TGF-beta-induced smad signal transduction pathway in human hypertrophic scar fibroblasts in vitro. Burns. 2012;38:404–413.
   PubMed Web of Science ®Google Scholar
• Granstein RD, Rook A, Flotte TJ, et al. A controlled trial of intralesional recombinant interferon-gamma in the treatment of keloidal scarring. Clinical and histologic findings. Arch Dermatol. 1990;126:1295–1302.
   PubMedGoogle Scholar
• Larrabee WF Jr., East CA, Jaffe HS, et al. Intralesional interferon gamma treatment for keloids and hypertrophic scars. Arch Otolaryngol Head Neck Surg. 1990;116:1159–1162.
   PubMedGoogle Scholar
• Williamson DA, Carter GP, Howden BP. Current and emerging topical antibacterials and antiseptics: agents, action, and resistance patterns. Clin Microbiol Rev. 2017;30:827–860.
   PubMedGoogle Scholar
• Sevgi M, Toklu A, Vecchio D, et al. Topical antimicrobials for burn infections - an update. Recent Pat Antiinfect Drug Discov. 2013 Dec;8(3):161–197.
   PubMedGoogle Scholar
• Poovey B. Hospitals are shutting down burn centers. The Washington Post. 2007. Available from: http://www.washingtonpost.com/wp-dyn/content/article/2007/08/08/AR2007080800272.html?noredirect=on
   Google Scholar
• New CDC report: more than 100 million Americans have diabetes or prediabetes. Centers for Disease Control and Prevention. 2017. Available from: https://www.cdc.gov/media/releases/2017/p0718-diabetes-report.html
   Google Scholar
• Maghsoudi H, Aghamohammadzadeh N, Khalili N. Burns in diabetic patients. Int J Diabetes Dev Ctries. 2008;28:19–25.
   PubMed Web of Science ®Google Scholar
• Briegel J, Bein T, Mohnle P. Update on low-dose corticosteroids. Curr Opin Anaesthesiol. 2017;30:186–191.
   PubMed Web of Science ®Google Scholar
• Batzofin BM, Weiss YG, Ledot SF. Do corticosteroids improve outcome for any critical illness? Curr Opin Anaesthesiol. 2013;26:164–170.
   PubMed Web of Science ®Google Scholar
• Li Z, Maitz P. Cell therapy for severe burn wound healing. Burns Trauma. 2018;6:13.
   PubMed Web of Science ®Google Scholar
• Rodgers K, Jadhav SS. The application of mesenchymal stem cells to treat thermal and radiation burns. Adv Drug Deliv Rev. 2018;123:75–81.
   PubMed Web of Science ®Google Scholar